BriaCell Therapeutics Cor...
(BCTXW)
undefined
undefined%
At close: undefined
0.34
-0.03%
After-hours Dec 13, 2024, 04:03 PM EST
Company Description
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies.
It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor.
It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT.
BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
BriaCell Therapeutics Corp.
| Country | CA |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. William V. Williams M.D. |
Contact Details
Address: Bellevue Centre West Vancouver, CA | |
| Website | https://briacell.com |
Stock Details
| Ticker Symbol | BCTXW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001610820 |
| CUSIP Number | n/a |
| ISIN Number | CA10778Y1126 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. William V. Williams M.D. | Chief Executive Officer, President & Director |
| Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer & Corporate Secretary |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Dec 12, 2024 | 424B5 | Filing |
| Dec 12, 2024 | SC 13D/A | [Amend] Filing |
| Dec 11, 2024 | 424B5 | Filing |
| Dec 10, 2024 | SC 13D/A | [Amend] Filing |
| Dec 05, 2024 | SC 13D/A | [Amend] Filing |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 01, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 10-K | Annual Report |